Robert Veltri, Ph.D. Associate Professor of Urology Johns Hopkins Medical Institutions Email:rveltri1@jhmi.edu

   INVENTIONS, PATENTS, COPYRIGHTS

1. Szent-Gyorgyi A, Fodor G, Veltri RW. 2-Furylbutyrolactone derivatives, their preparation, compositions containing them, and their use for modulation of the immune system in mammals. Patent No. 4,518,611; Issued: May 21,1985. Assigned to Theracel Corp., Rockville , MD.
2. Veltri RW, Maxim PE, Fodor G. 2-Furylbutyrolactone modulation of the immune system in mammals. Patent No. 4,518,611 issued 05-21-85. Assigned to Theracel Corp., Rockville, MD.
3. Maxim PE and Veltri RW. Assaying for circulating immune complexes with labeled protein A. Patent No. 4,617,262, Issued October 14, 1986. Assigned to CooperBiomedical Inc., Palo Alto, CA.
4. Veltri, RW and Maxim PE. Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones. Patent No. 4,883,813, Issued November 28, 1989. Assigned to Theracel Corp., Rockville, MD.
5. Fodor G, Sussangkarn K. and Veltri RW. Condensation products of cyclic diketones and ascorbic acid as immunomodulatory agents. Patent No. 4,883,808 issued 11-28-89. Assigned to Theracel Corp., Rockville, MD.
6. Fox, SW and Veltri RW. Microencapsulated antitumor agent. Patent No. 4,963,364, Issued October 16, 1990. Assigned to the inventors.
7. Veltri RW, Fodor G, and Sussangkarn K. Pharmaceutically useful furyl substituted dihydroxyethylbutyrolactones. Patent No. 5,102,909 issued 04-07-92. Assigned to Theracel Corp., Rockville, MD.
8. Veltri RW and Fodor G. Pharmaceutically useful Michael addition products of unsaturated aldehydes and ketones and ascorbic acid. Patent No. 5,098,933 issued 03-24-92. Assigned to Theracel Corp., Rockville, MD.
9. An G, O’Hara SM, Ralph DA and Veltri RW. Biomarkers and targets for diagnosis, prognosis and management of prostate disease. Patent No. 5,882,864 issued 03-16-1999. Assigned to UroCor, Inc., Oklahoma City, OK.
10. Gang An and Robert W. Veltri Biomarkers and targets for diagnosis, prognosis and management of prostate diseases. Patent No. 5,972,615. Issued October 26, 1999. Assigned to UroCor, Inc., Oklahoma City, OK.
11. Gang An, Veltri RW et al Biomarkers and targets for diagnosis, prognosis and management of prostate, breast, and bladder cancer. Patent Number 6,218,529 issued on 4/1/2001., Assigned to UroCor, Inc., Oklahoma City, OK.
12. Garry M. Marley and R.W. Veltri. Method for Selectively Inducing Biomarker Expression in Urologic Tumor Tissue for Diagnosis and Treatment Thereof. Patent No. 5,856,112 issued 01-5-1999. Assigned to UroCor, Inc., Oklahoma City, OK.
13. Veltri RW, Miller MC, Bacus MP, Ashenayi K. A sextant core biopsy predictive mechanism for non-organ-confined disease status”. Issued November 23, 1999. Patent No. 5,989,811, issued 09-29-2000. Assigned to UroCor, Inc., Oklahoma City, OK.
14. Robert W. Veltri, Michael P. Bacus, M. Craig Miller. Prediction of Prostate Cancer Progression by Analysis of Selected Biomarkers. Patent No. 6,025 128, issued 02-15-2000. Assigned to UroCor, Inc., Oklahoma City, OK.
15. Gang An and RW Veltri. A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,156,515 Issued December 5, 2000. Assigned to UroCor.
16. Ralph DA, An G, and Veltri RW. Diagnosis of disease state using mRNA profiles in peripheral leukocytes. Patent No. 6,190,857 issued February 20, 2001. Assigned to UroCor, Inc., Oklahoma City, OK.
17. An, Gang and Veltri, Robert. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer. Patent No. 6,369,195 issued April 9, 2002. Assigned to UroCor, Inc., Oklahoma City, OK.
18. Veltri, Robert W., Ashenayi, Kaveh, Hu, Ying and O'Dowd, Gerard J. Neural network for cell image analysis for identification of abnormal cells. Patent No. 6,463,438 issued October 8, 2002. Assigned to UroCor, Inc., Oklahoma City, OK.
19. Veltri RW. Trademark, “UroScoreTM”. Serial No. 7468233 registered January 16, 1996 to UroCor Inc., Oklahoma City, OK. Registration No. 1948820 for Laboratory research services in the field of oncology.
20. Veltri RW. Trademark, Quantitative Nuclear Grade “QNG^TM”. Serial No. 76173213 registered March 19, 2002 to UroCor Inc. of Oklahoma City, OK. Registration No. 2549632 for Medical services for detecting, staging, and prognosis of cancer.